LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)
Naveen Vasudev(University of Leeds), T.B. Powles(Queen Mary University of London), Karen Fife(Cambridge University Hospitals NHS Foundation Trust), Archit Jain(The Royal Wolverhampton NHS Trust), Fiona Collinson(St James's University Hospital), Galina Velikova(University of Leeds), J.E. Brown(University of Sheffield), L. Pickering(Royal Marsden NHS Foundation Trust), Stefan N. Symeonides(NHS Lothian), Gemma Ainsworth(University of Leeds), Anthony Maraveyas(University of Hull), Richard W. Griffiths(Clatterbridge Cancer Centre NHS Foundation Trust), Sarah Brown(University of Leeds), Ambudhar Sharma(Mount Vernon Cancer Centre), Paul Nathan(Mount Vernon Hospital), Eszter Katona(University of Leeds), Tom Waddell(The Christie NHS Foundation Trust), Helen Howard(University of Leeds), B. Venugopal(Beatson West of Scotland Cancer Centre), Pragna Patel(Nottingham City Hospital)
Cited by 9
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869